The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical readouts and IPOs were among the catalysts for the week.
Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab in China
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)))), an innovative commercial-stage biopharmaceutical company, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)
Zai Lab Q2 EPS $(1.76) Misses $(1.30) Estimate, Sales $36.94M Beat $28.26M Estimate
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(1.76) per share which missed the analyst consensus estimate of $(1.30) by 35.38 percent. This is a 28.47 percent decrease over losses of $(1.37) per share from the same period last year.
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
Schrödinger, Zai Lab Team Up For Cancer Program Targeting DNA Damage Response
Schrödinger Inc (NASDAQ:SDGR) and Zai Lab Limited (NASDAQ:ZLAB) have collaborated to discover, develop, and commercialize oncology candidate targeting DNA damage response. The research…
Schrödinger And Zai Lab Announce A Global R&D Collaboration In Oncology; Schrödinger Eligible To Receive Up To $338M In Milestone Payments
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, and Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)), an innovative
MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal
MacroGenics Inc (NASDAQ:MGNX) and Zai Lab Limited (NASDAQ:ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules.…
MacroGenics And Zai Lab Enter Collaboration To Develop And Commercialize Preclinical Bispecific Antibodies in Oncology; MacroGenics To Receive Initial Consideration Of $55M, An Equity Investment And Is Eligible For $1.4B In Milestones
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules
MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms